25 Breast Cancer Clinical Trials in Dallas, PA (2026)

Q: How do I join a clinical trial in Dallas?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you.

Recruiting Breast Cancer Studies in Dallas

NCT05654246Recruiting

Susan G. Komen's ShareForCures

ShareForCures (SFC) is a community-based participatory research registry, and its prime objective is to engage participants representative of the United States breast cancer patient population -includ...

Dallas, PA200,000 participantsSusan G. Komen Breast Cancer Foundation

View Study Details

NCT06085833Recruiting

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the ...

Dallas, PA2,706 participantsARTIDIS AG

View Study Details

NCT05867251Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients...

Dallas, PA430 participantsAvenzo Therapeutics, Inc.

View Study Details

NCT06797635Recruiting

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The ma...

Dallas, PA372 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07604571Recruiting

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients ...

Dallas, PA194 participantsNovartis Pharmaceuticals

View Study Details

NCT05898399Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Niraparib....

Dallas, PA181 participantsArtios Pharma Ltd

View Study Details

NCT06022029Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expan...

Dallas, PA168 participantsOncoNano Medicine, Inc.

View Study Details

NCT03562273Recruiting

GammaPod Registry and Quality of Life Nomogram

This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a si...

Dallas, PA160 participantsUniversity of Maryland, Baltimore

View Study Details

NCT07540572Recruiting

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary ef...

Dallas, PA160 participantsIDEAYA Biosciences

View Study Details

NCT03804944Recruiting

Converting HR+ Breast Cancer Into an Individualized Vaccine

Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 mo...

Dallas, PA100 participantsWeill Medical College of Cornell University

View Study Details

NCT06926920Recruiting

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNB...

Dallas, PA100 participantsGilead Sciences

View Study Details

NCT07408089Recruiting

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults wit...

Dallas, PA96 participantsBoundless Bio, Inc.

View Study Details

NCT06999187Recruiting

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refra...

Dallas, PA96 participantsDren Bio

View Study Details

NCT05573126Recruiting

Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, an...

Dallas, PA95 participantsEllipses Pharma

View Study Details

NCT05245812Recruiting

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

This is a single arm, single-center, prospective clinical trial designed to track the peri, post-operative and oncologic outcomes when utilizing the da-Vinci single port (SP) robotic platform to perfo...

Dallas, PA90 participantsDeborah Farr, MD

View Study Details

NCT06875128Recruiting

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with breast cancer that has spread to ...

Dallas, PA90 participantsDelcath Systems Inc.

View Study Details

NCT05693766Recruiting

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone recept...

Dallas, PA64 participantsSonya Reid

View Study Details

NCT04614194Recruiting

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

The purpose of this study is to better understand how the immune system plays a role in fighting breast cancer and specifically research if the immune system response against breast cancer can be impr...

Dallas, PA60 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT06444269Recruiting

Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial

1\. Efficacy of PULSAR preoperative radiation 2. Evaluate potential of microbubble CEUS as an alternative to operative SLNBx 3. Evaluate potential of OA to evaluate treatment response of pre-operative...

Dallas, PA53 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT06517212Recruiting

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), nod...

Dallas, PA48 participantsBaylor Research Institute

View Study Details

NCT05748834Recruiting

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals...

Dallas, PA36 participantsSCRI Development Innovations, LLC

View Study Details

NCT05029999Recruiting

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil...

Dallas, PA30 participantsUniversity of Texas Southwestern Medical Center

View Study Details

NCT05919108Recruiting

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of me...

Dallas, PA30 participantsVanderbilt-Ingram Cancer Center

View Study Details

NCT04265872Recruiting

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

The hypothesis of this pilot trial is that administration of bortezomib will inhibit NHEJ in metastatic TNBC leading at the time of disease progression to metastases that are HR-deficient and sensitiv...

Dallas, PA20 participantsBaylor Research Institute

View Study Details

NCT06008275Recruiting

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

The goal of this clinical trial is to assess the safety and efficacy of combined ruxolitinib and neratinib in patients with chemotherapy-pretreated metastatic triple negative breast cancer. This trial...

Dallas, PA20 participantsBaylor Research Institute

View Study Details

About Breast Cancer Clinical Trials in Dallas

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 25 breast cancer clinical trials recruiting participants in Dallas, PA. These studies are seeking a combined 205,399 participants. Research is being sponsored by Susan G. Komen Breast Cancer Foundation, ARTIDIS AG, Avenzo Therapeutics, Inc. and 18 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Dallas — FAQ

Are there breast cancer clinical trials in Dallas?

Yes, there are 25 breast cancer clinical trials currently recruiting in Dallas, PA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Dallas?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Dallas research site will contact you about next steps.

Are clinical trials in Dallas free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Dallas studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 25 active trials in Dallas are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 13, 2026 from ClinicalTrials.gov